[Federal Register Volume 77, Number 199 (Monday, October 15, 2012)]
[Pages 62515-62516]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-25251]



Centers for Disease Control and Prevention


Proposed Data Collections Submitted for Public Comment and 

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-639-7570 
and send comments to Ronald Otten, CDC Reports Clearance Officer, 1600 
Clifton Road, MS-D74, Atlanta, GA 30333 or send an email to 
[email protected].
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Well-Integrated Screening and Evaluation for Women Across the 
Nation (WISEWOMAN) Reporting System (OMB 0920-0612, exp. 3/31/
2013)--Extension--National Center for Chronic Disease Prevention and 
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention 

Background and Brief Description

    Cardiovascular disease (CVD), which includes heart disease, 
myocardial infarction, and stroke, is the leading cause of death for 
women in the United States, and is largely preventable. The WISEWOMAN 
program (Well-Integrated Screening and Evaluation for Women Across the 
Nation), administered by the Centers for Disease Control and Prevention 
(CDC), was established to examine ways to improve the delivery of 
services for women who have limited access to health care and elevated 
risk factors for CVD. The program focuses on reducing CVD risk factors 
and provides screening services for select risk factors such as 
elevated blood cholesterol, hypertension and abnormal blood glucose 
levels. The program also provides lifestyle interventions and medical 
referrals. On an annual basis, 21 grantees funded through the WISEWOMAN 
program have provided services to approximately 30,000 women who are 
already participating in the National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP), also administered by CDC.
    CDC currently collects information from WISEWOMAN grantees to 
support continuous program monitoring and improvement activities. CDC 
seeks to extend OMB approval for one additional year. There are no 
changes to the number of respondents, the data items reported to CDC, 
the estimated burden per response, or the total estimated annualized 
burden. All information will continue to be collected twice per year.
    Information reported to CDC includes baseline and follow-up data 
(12 months post enrollment) for all women served through the WISEWOMAN 
program. These data, called the minimum data elements (MDE), include 
data elements that describe risk factors for the women served in each 
program and data elements that describe the number and type of 
intervention sessions attended. Funded grantees compile the data from 
their existing databases and report the MDE to CDC on April 15th and 
October 15th of each year.
    The MDE data provide an assessment of how effective the WISEWOMAN 
program is at reducing the burden of cardiovascular disease risk 
factors among women who utilize program services. The information 
collected from grantees is also used to assess the cost-effectiveness 
and impact of the program. Because certain demographic information has 
already been collected as part of NBCCEDP, the additional burden of 
WISEWOMAN program reporting is modest.
    The overall program evaluation is designed to demonstrate how 
WISEWOMAN can obtain more complete health data on vulnerable 
populations, promote public education about disease incidence and risk-
factors, improve the availability of screening and diagnostic services 
for under-served women, ensure the quality of services provided to 
under-served women, and develop strategies for improved interventions. 
The information reported to CDC also includes programmatic information 
related to grantee management, public education and outreach, 
professional education, service delivery, cost, and progress toward 
meeting stated programmatic objectives.
    All MDE information will be submitted to CDC electronically. The 
estimated burden per response for Screening and Assessment MDE is 16 
hours. The estimated burden per response for Lifestyle Intervention MDE 
is 8 hours. Progress reports will be submitted in hardcopy format. The 
estimated burden per response for each progress report is 16 hours.

[[Page 62516]]

                                        Estimated Annualized Burden Hours
                                                     Number of       Number of      burden  per    Total  burden
      Type of respondent            Form name       respondents   responses  per   response  (in      (in hr)
                                                                     respondent         hr)
WISEWOMAN Grantees............  Screening and                 21               2              16             672
                                 Assessment MDE.
                                Lifestyle                     21               2               8             336
                                Progress Report.              21               2              16             672
    Total.....................  ................  ..............  ..............  ..............           1,680

    Dated: October 9, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate 
Director for Science (OADS), Office of the Director, Centers for 
Disease Control and Prevention.
[FR Doc. 2012-25251 Filed 10-12-12; 8:45 am]